BMC Medical Education Образование
Development and educational evaluation of iLN, a DeepSeek-based generative AI platform for teaching lupus nephritis: a randomized controlled, single-blind (outcome assessor-blinded) study
Аннотация
Background Lupus nephritis (LN) is the most common and severe organ manifestation of systemic lupus erythematosus, and its diagnosis and treatment require the integration of clinical, serological, and renal pathological information. Few studies have evaluated generative artificial intelligence (GAI)-assisted teaching dedicated to LN training. Methods We developed an interactive LN teaching platform (iLN) based on the DeepSeek large language model, integrating current textbooks, guidelines, a renal pathology atlas, and authentic cases across seven modules. In a randomized controlled study, 50 third-year medical students were randomized in a 1:1 ratio to iLN-based multimodal teaching (iLN group) or traditional lectures (control group). Randomization was performed using a random number table after all participants had been enrolled, and the outcome assessor was blinded to group allocation. The primary outcome was an immediate postintervention 20-item multiple-choice examination (100 points). Results The iLN group achieved a higher median score compared to the control group (median 90 [IQR 90–95] vs. 75 [IQR 75–80]; Hodges–Lehmann median difference of 15.0 points, 95% CI 10.0–20.0; Mann–Whitney U test P < 0.001). There was no significant difference in score dispersion between the groups, as the 95% confidence interval for the ratio of standard deviations included 1.0. The nominally smaller standard deviation does not provide evidence that the platform reduced variation in learning outcomes. Additionally, iLN students reported a high satisfaction rate of 96.0%. Conclusions The iLN platform was associated with higher immediate post-intervention test scores and high student satisfaction, supporting the feasibility of integrating generative AI into a multicomponent platform for LN. Larger multicenter studies with validated instruments and long-term follow-up are required. Trial registration NCT07706998 (retrospectively registered on June 30, 2026).